Trial Profile

A 48-Month, Multi-Centre, Observational Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efmoroctocog alfa (Primary)
Indications Haemophilia A
Focus Therapeutic Use
Acronyms A-MORE
Sponsors Swedish Orphan Biovitrum

Most Recent Events

28 Jan 2025 According to Sobi media release, Interim Analysis data from this study to be presented at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Milan from the 4th - 7th February, 2025.
17 Jun 2024 According to Sobi media release, data from third interim analysis of up to 24 months will be presented at ISTH 2024, the 32nd Congress of the International Society on Thrombosis and Haemostasis. This event, taking place from 22nd to 26th June.
10 Apr 2024 Planned End Date changed from 1 Dec 2025 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com